262 related articles for article (PubMed ID: 15721388)
1. Liposomal polyene antibiotics.
Ng AW; Wasan KM; Lopez-Berestein G
Methods Enzymol; 2005; 391():304-13. PubMed ID: 15721388
[TBL] [Abstract][Full Text] [Related]
2. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
3. Polyene antibiotics: relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content.
Zager RA
Am J Kidney Dis; 2000 Aug; 36(2):238-49. PubMed ID: 10922301
[TBL] [Abstract][Full Text] [Related]
4. Development of liposomal polyene antibiotics: an historical perspective.
Ng AW; Wasan KM; Lopez-Berestein G
J Pharm Pharm Sci; 2003; 6(1):67-83. PubMed ID: 12753730
[TBL] [Abstract][Full Text] [Related]
5. Lipid-based antifungal agents: a concise overview.
Arikan S
Cell Mol Biol Lett; 2002; 7(3):919-22. PubMed ID: 12378276
[TBL] [Abstract][Full Text] [Related]
6. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease.
Moribe K; Maruyama K
Curr Pharm Des; 2002; 8(6):441-54. PubMed ID: 12069381
[TBL] [Abstract][Full Text] [Related]
8. Effect of cholesterol in various liposomal compositions on the in vivo toxicity, therapeutic efficacy, and tissue distribution of amphotericin B.
Ahmad I; Sarkar AK; Bachhawat BK
Biotechnol Appl Biochem; 1990 Oct; 12(5):550-6. PubMed ID: 2288711
[TBL] [Abstract][Full Text] [Related]
9. Diversity of lipid-based polyene formulations and their behavior in biological systems.
Wasan KM; Lopez-Berestein G
Eur J Clin Microbiol Infect Dis; 1997 Jan; 16(1):81-92. PubMed ID: 9063678
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
Allen TM; Mumbengegwi DR; Charrois GJ
Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
[TBL] [Abstract][Full Text] [Related]
11. Drug delivery by lipid cochleates.
Zarif L
Methods Enzymol; 2005; 391():314-29. PubMed ID: 15721389
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
13. Commercially available lipid formulations of amphotericin b: are they bioequivalent and therapeutically equivalent?
Cifani C; Costantino S; Massi M; Berrino L
Acta Biomed; 2012 Aug; 83(2):154-63. PubMed ID: 23393924
[TBL] [Abstract][Full Text] [Related]
14. [Anti-infectious effect of sustained antravitreal amphotericin B drug delivery system on experimental rabbit fungal endophthalmitis of Candida albicans].
Chen N; Yang YT; Dong XG; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2006 May; 42(5):420-5. PubMed ID: 16762236
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B.
Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ
Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826
[TBL] [Abstract][Full Text] [Related]
16. Liposome-based drug delivery to alveolar macrophages.
Vyas SP; Khatri K
Expert Opin Drug Deliv; 2007 Mar; 4(2):95-9. PubMed ID: 17335407
[TBL] [Abstract][Full Text] [Related]
17. Liposomal amphotericin B: clinical experience and perspectives.
Gibbs WJ; Drew RH; Perfect JR
Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
[TBL] [Abstract][Full Text] [Related]
18. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
[TBL] [Abstract][Full Text] [Related]
19. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
20. [Prostaglandin synthetase activity in the different layers of the kidneys of young rats exposed to polyene antibiotics].
Efendiev AM; Pomoĭnetskiĭ VD; Kubatiev AA
Biull Eksp Biol Med; 1986 Mar; 101(3):302-4. PubMed ID: 3082383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
